BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:iLeukon Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies iLeukon Therapeutics\, Inc.'s dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07452224-2538@assetmemo.bio
DTSTAMP:20261121T005946Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:ILKN421H: Phase 2 readout est. (NCT07452224)
DESCRIPTION:ILKN421H\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: ILKN42
 1H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer\nEstimated pr
 imary completion: June 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ilkn421h#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07452224
URL:https://assetmemo.bio/drug/ilkn421h#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
